OUR APPROACHInnovating to transform medicine. Our experience in vaccines and rare diseases has allowed us, within a few years, to become a major biotechnology player: 72% of molecules under development in our pipeline are biological. This shift enables us to ramp up our research and improve efficiency. In 2015, the launch of the first dengue vaccine, Dengvaxia®, was a major step in medical progress. In parallel, we are continuing our chemistry-based research initiatives, in a multidisciplinary scientific approach.
Working for and with patients. We have transformed our research model to continuously offer patients more innovative solutions and respond effectively to public health emergencies. We have shortened our product development cycle—with an average clinical cycle lasting roughly five years, we are among the five fastest laboratories in medication development. We focus on high-value projects, whose prospects can change patients’ lives or reduce threats of epidemics. In early 2016, we launched a vaccination research program against the Zika virus in response to the call by the World Health Organization (WHO).
Increasing innovation and sharing expertise. Scientific collaborations are, for us, one of the crucial elements of success in R&D. We share skills and projects with the best scientists and the highest performing companies in each therapeutic area. In 2015, we signed more than 75 research agreements with partners around the world. For example: Verily (formerly Google Life Science), BioNTech, Evotec, Innate Pharma, Lexicon, Hanmi and Regeneron. While strengthening our research portfolio with our R&D teams, we develop a network of scientific excellence, in order to deliver great quality innovations with high added value.
bn budget invested in R&D in 2015. €6 bn annual budget expected by 2020